Evaluation of ICP-B381 in Patients With Advanced Solid Tumors
2026年11月13日 更新者:Beijing InnoCare Pharma Tech Co., Ltd.
An Open, Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics Characteristics, and Efficacy of ICP-B381 in Participants With Advanced Solid Tumors
To evaluate the safety, tolerability, efficacy and pharmacokinetic characteristics of ICP-B381 in the trial participants of advanced solid tumors
研究概览
地位
地位
招聘中
干预/治疗
干预/治疗
研究类型
研究类型
介入性
注册 (估计的)
注册
348
阶段
阶段
- 阶段2
- 阶段1
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习联系方式
学习联系方式
- 姓名:Jingnan Yang
- 电话号码:010-66609990
- 邮箱:CO-Clinicaltrial@innocarepharma.com
学习地点
-
-
Shanghai Municipality
-
Shanghai、Shanghai Municipality、中国、200032
- 招聘中
- Fudan University Shanghai Cancer Center
-
接触:
- DingWei Ye, M.D.
- 电话号码:021-64175590*81807
- 邮箱:dwyeli@163.com
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
资格标准
适合学习的年龄
18年 及以上 (成人、年长者)
接受健康志愿者
不
有资格学习的性别
全部
描述
Inclusion Criteria:
- Participants must be at least 18 years old.
- Participants thoroughly understand study procedures, and voluntarily sign the written ICF
- Eastern Cooperative Oncology Group (ECOG) performance status score 0-1.
- Expected survival time ≥3 months.
- Histopathologically confirmed metastatic castration-resistant prostate cancer (mCRPC) & Other advanced solid tumor
- Agree to provide FFPE slides from archived tumor tissues collected within the past 2 years or fresh tumor biopsies (for archived samples, more recently collected specimens are preferred
- The organ function level must meet the prescribed standards
- All toxicities derived from previous anti-neoplasm treatments must have been resolved to Grade ≤1 (per CTCAE V6.0)
- Effective contraceptive measures should be taken from the date of signing the informed consent form until at least 6 months after the use of the last dose of the study drug
- Female participant of childbearing potential must have a negative blood pregnancy test at the screening visit
- Female participants must not breastfeed or plan pregnancy during the study and for at least 6 months after the last dose.
- Participants can communicate well with the Investigator and can complete the study according to the study protocol
Exclusion Criteria:
- Other active malignant tumors occurred within 3 years before the first administration of the study drug
- Has previously received or is currently receiving the same type of drug or related treatment as stipulated in the protocol
- Has a previous medical history and adverse life history as specified in the protocol, or has a disease as specified in the protocol
- Has received cytotoxic chemotherapy, radical radiotherapy, molecular targeted therapy, immunotherapy, anti-tumor vaccine therapy, cytokine therapy, or other investigational anti-cancer drugs with an elution time not meeting the protocol requirements
- Had active bleeding within 2 months before screening or had clinically significant or significant bleeding tendency, or was experiencing bleeding symptoms due to taking anticoagulant drugs or other medical interventions
- Had major surgery within 28 days before the first administration or minor surgery within 2 weeks before the first administration
- Has received systemic immunosuppressive drugs as stipulated in the protocol for 14 days before the first administration
- Has a history of severe allergic reactions to the active ingredient, non-active ingredients in the drug, or antibody-based drugs
- Had the first administration within 2 weeks before or is planned to use drugs or foods with strong inhibitory or inducing effects on cytochrome P450 CYP3A before the study
- Has any mental or cognitive disorders that may limit their understanding, execution of the informed consent form, and compliance with the study
- Situations that the investigator deems unsuitable for participating in this study
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:顺序分配
- 屏蔽:无(打开标签)
手臂数量
1
武器和干预
参与者组/臂参与者组/臂 |
干预/治疗干预/治疗 |
|---|---|
|
实验性的:ICP-B381
|
ICP-B381 will be administered by intravenous infusion every 3 weeks (Q3W) until disease progression (PD) or the occurrence of unacceptable toxicity or withdrawal from the study for other reasons (whichever occurs first). |
研究衡量的是什么?
主要结果指标
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
The type, severity (assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 6.0 [NCI-CTCAE V6.0]), relationship to the investigational product, and incidence rate of adverse event (AE) and serious advers
大体时间:2 years
|
2 years
|
|
The type, severity (assessed according to NCI-CTCAE V6.0), and incidence rate of dose limiting toxicity (DLT)
大体时间:2 years
|
2 years
|
|
Single-agent Recommended Dose (RD) and/or Maximum Tolerated Dose (MTD)
大体时间:2 years
|
2 years
|
|
Participants with prostate cancer: Prostate-specific antigen (PSA50) response rate
大体时间:2 years
|
2 years
|
|
Participants with other tumor types: Investigator-assessed Objective response rate (ORR)
大体时间:2 years
|
2 years
|
|
The optimal dosing regimen for the subsequent study of ICP-B381
大体时间:2 years
|
2 years
|
次要结果测量
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
总生存期(OS)
大体时间:2年
|
2年
|
|
缓解持续时间 (DOR)
大体时间:2年
|
2年
|
|
客观缓解率 (ORR)
大体时间:2年
|
2年
|
|
最大浓度 (Cmax)
大体时间:2年
|
2年
|
|
疾病控制率(DCR)
大体时间:2年
|
2年
|
|
Time to Maximum Plasma Concentration (Tmax)
大体时间:2 years
|
2 years
|
|
Half-life (T1/2)
大体时间:2 years
|
2 years
|
|
Area Under the Serum or Plasma Concentration-Time Curve (AUC0-∞ and AUC0-t)
大体时间:2 years
|
2 years
|
|
Apparent Clearance Rate (CL/F)
大体时间:2 years
|
2 years
|
|
Terminal Apparent Volume of Distribution (Vz/F)
大体时间:2 years
|
2 years
|
|
Steady-state Pharmacokinetic Parameters
大体时间:2 years
|
2 years
|
|
Participants with prostate cancer: radiographic progression-free survival (rPFS) evaluated by the Investigator according to RECIST V1.1 criteria (for soft tissue lesions) and PCWG3 criteria (for bone lesions)
大体时间:2 years
|
2 years
|
|
Participants with prostate cancer: changes in serum PSA levels compared to baseline during the study: PSA50 response rate
大体时间:2 years
|
2 years
|
|
Participants with prostate cancer: PSA90 response rate
大体时间:2 years
|
2 years
|
|
Participants with prostate cancer:12-week PSA response rate
大体时间:2 years
|
2 years
|
|
Participants with prostate cancer: time to PSA progression (TTPP)
大体时间:2 years
|
2 years
|
|
Time to First Subsequent Therapy (TFST)
大体时间:2 years
|
2 years
|
|
Participants with prostate cancer: incidence rate of symptomatic skeletal event (SSE)
大体时间:2 years
|
2 years
|
|
Participants with prostate cancer: time to first symptomatic skeletal event (TTSSE)
大体时间:2 years
|
2 years
|
|
Incidence rate of anti-drug antibody (ADA) against ICP-B381
大体时间:2 years
|
2 years
|
|
Types, severity (assessed according to NCI-CTCAE V6.0), relationship with the investigational product, and incidence rate of AE and SAE
大体时间:2 years
|
2 years
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
学习开始
2026年10月30日
初级完成 (估计的)
初级完成
2027年9月1日
研究完成 (估计的)
研究完成
2028年7月1日
研究注册日期
首次提交
首次提交
2026年10月22日
首先提交符合 QC 标准的
首先提交符合 QC 标准的
2026年10月22日
首次发布 (实际的)
首次发布
2026年10月28日
研究记录更新
最后更新发布 (实际的)
最后更新发布
2026年11月18日
上次提交的符合 QC 标准的更新
上次提交的符合 QC 标准的更新
2026年11月13日
最后验证
最后验证
2026年11月1日
更多信息
与本研究相关的术语
其他研究编号
其他研究编号
- ICP-CL-01901
药物和器械信息、研究文件
研究美国 FDA 监管的药品
不
研究美国 FDA 监管的设备产品
不
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.